A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-1183PMID 17062687PMCID PMC2154351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

  2005cited by this paper
• HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

  2005cited by this paper
• Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

  2005cited by this paper
• Supernatural T cells: genetic modification of T cells for cancer therapy

  2005cited by this paper
• Engineering T cells for cancer therapy

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Genetic modification of T lymphocytes for adoptive immunotherapy.

  2004cited by this paper
• Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

  2004cited by this paper
• Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients.

  2004cited by this paper
• Anti‐prostate specific membrane antigen designer T cells for prostate cancer therapy

  2004cited by this paper
• Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells

  2004cited by this paper
• Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.

  2003cited by this paper
• Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation

  2003cited by this paper
• Quantitative imaging of the T cell antitumor response by positron-emission tomography

  2003cited by this paper
• Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

  2002cited by this paper
• Dual-specific T cells combine proliferation and antitumor activity

  2002cited by this paper
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

  2002cited by this paper
• Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.

  2000cited by this paper
• Expansion and Characterization of T Cells Transduced with a Chimeric Receptor against Ovarian Cancer

  2000cited by this paper
• Anti-Tumor CC49-ζ CD4 T Cells Possess Both Cytolytic and Helper Functions

  2000cited by this paper
• Level of anti‐mouse‐antibody response induced by bi‐specific monoclonal antibody OC/TR in ovarian‐carcinoma patients is associated with longer survival

  1999cited by this paper
• Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.

  1998cited by this paper
• Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.

  1996cited by this paper
• Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer

  1996cited by this paper
• In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.

  1995cited by this paper
• Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19.

  1994cited by this paper
• Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response

  1994cited by this paper
• Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain

  1993cited by this paper
• Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.

  1991cited by this paper
• Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.

  1990cited by this paper
• In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.

  1989cited by this paper
• Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity

  1987cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986cited by this paper
• Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.

  1986cited by this paper
• Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.

  1985cited by this paper

• Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges

  2026cites this paper
• CAR-engineered cell therapies: current understandings and future perspectives

  2026cites this paper
• The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology.

  2026cites this paper
• Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer.

  2026cites this paper
• Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.

  2026cites this paper
• Current state of CAR-T cell therapies for solid tumors.

  2026cites this paper
• Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.

  2026cites this paper
• Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma

  2026cites this paper
• Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms

  2026cites this paper
• CAR-T Cell Therapy for Central Nervous System Tumors.

  2026cites this paper
• The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma

  2025cites this paper
• Tracing the development of CAR-T cell design: from concept to next-generation platforms

  2025cites this paper
• In vivo nano-engineering T cells for CAR-T therapy.

  2025cites this paper
• Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications

  2025cites this paper
• Chimeric antigen receptor T cell therapy for autoimmune diseases.

  2025cites this paper
• Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors

  2025cites this paper
• CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions

  2025cites this paper
• Interfacial T cell engineering

  2025cites this paper
• Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives

  2025cites this paper
• Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products

  2025cites this paper
• Cell therapies for immune-mediated disorders

  2025cites this paper
• Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer

  2025cites this paper
• CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management

  2025cites this paper
• Nanobodies and their derivatives: pioneering the future of cancer immunotherapy

  2025cites this paper
• Zelluläre Therapieverfahren in der Inneren Medizin

  2025cites this paper
• Engineering B cells to treat and study human disease

  2025cites this paper
• CAR Cell-Derived Exosomes in Cancer Therapy: Biogenesis, Engineering Strategies and Antitumor Mechanisms

  2025cites this paper
• CAR-T cell therapy: A therapeutic strategy for cancer treatment.

  2025cites this paper
• Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells

  2025cites this paper
• Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors

  2025cites this paper
• Frontline pemetrexed and cisplatin based-chemotherapy combined with NRT promoted the antitumor in a mouse model of lung carcinoma.

  2025cites this paper
• Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer

  2025cites this paper
• CAR-T Cell Therapy for Solid Tumors

  2025cites this paper
• The potential of chimeric antigen receptor -T cell therapy for endocrine cancer

  2025cites this paper
• Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model

  2025cites this paper
• CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC.

  2025cites this paper
• Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma

  2025cites this paper
• GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions

  2025cites this paper
• Optimal chemokine receptors for enhancing immune cell trafficking in adoptive cell therapy

  2025cites this paper
• Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age

  2025cites this paper
• Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors

  2025cites this paper
• Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.

  2025cites this paper
• Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.

  2025cites this paper
• Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects: A comprehensive review.

  2025cites this paper
• Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

  2025cites this paper
• Current Role of CAR-T Therapy in Haematological Care.

  2025cites this paper
• CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer

  2025cites this paper
• Cell-Based Therapies for Solid Tumors: Challenges and Advances

  2025cites this paper
• Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy

  2025cites this paper
• CAR-T cell therapy for cancer: current challenges and future directions

  2025cites this paper
• Exosome: The hidden messengers in cancer detection and immunotherapy.

  2025cites this paper
• Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer

  2025cites this paper
• Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors

  2025cites this paper
• Tunneling CARs: Increasing CAR T-cell tumor infiltration through the overexpression of MMP-7 and Osteopontin-b.

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

  2025cites this paper
• Chimeric antigen receptor T cell therapy for autoimmune disease

  2024cites this paper
• CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects

  2024cites this paper
• Boosting CAR-T cell therapy with CRISPR technology

  2024cites this paper
• Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.

  2024cites this paper
• Biomaterial‐Based Therapeutic Delivery of Immune Cells

  2024cites this paper
• New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review

  2024cites this paper
• Biomaterials‐Boosted Immunotherapy for Osteosarcoma

  2024cites this paper
• Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.

  2024cites this paper
• CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?

  2024cites this paper
• Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy

  2024cites this paper
• Chimeric Antigen Receptor T-Cells (CAR T-Cells): An Engineered Targeted Therapy for Treatment of Cancer

  2024cites this paper
• CAR-T cell-derived exosomes: a new perspective for cancer therapy

  2024cites this paper
• Development of Personalized Strategies for Precisely Battling Malignant Melanoma

  2024cites this paper
• Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion

  2024cites this paper
• TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors

  2024cites this paper
• CRISPR/Cas9 Application in CAR-T Cell Based Tumor Therapies

  2024cites this paper
• CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

  2024cites this paper
• Prospects and challenges of CAR-T in the treatment of ovarian cancer.

  2024cites this paper
• Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology

  2024cites this paper
• Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations

  2024cites this paper
• CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2024cites this paper
• The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

  2024cites this paper
• Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment

  2024cites this paper
• The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?

  2024cites this paper
• Adoptive T cell therapy for ovarian cancer.

  2024cites this paper
• Activity of Potassium Channels in CD8+ T Lymphocytes: Diagnostic and Prognostic Biomarker in Ovarian Cancer?

  2024cites this paper
• Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin

  2024cites this paper
• Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites

  2024cites this paper
• Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

  2024cites this paper
• The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

  2024cites this paper
• Folate Receptor Alpha—A Novel Approach to Cancer Therapy

  2024cites this paper
• Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review

  2024cites this paper
• Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer

  2024cites this paper
• Nanofibrous MultiDomain Peptide Hydrogels Provide T Cells a 3D, Cytocompatible Environment for Cell Expansion and Antigen-Specific Killing.

  2024cites this paper
• Car T Cells in Solid Tumors: Overcoming Obstacles

  2024cites this paper
• State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?

  2024influential citation
• PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

  2024cites this paper
• CAR-T cell therapy for breast cancer: Current status and future perspective.

  2024cites this paper
• Revolutionizing cancer treatment: the rise of personalized immunotherapies

  2024cites this paper
• Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity

  2024cites this paper
• A Thermo-responsive collapse system for controlling heterogeneous cell localization, ratio and interaction for three-dimensional solid tumor modeling

  2024cites this paper
• The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances

  2024cites this paper